ALX Oncology’s (ALXO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research report sent to investors on Tuesday morning,Benzinga reports.

Other research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a report on Tuesday, August 13th. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Lifesci Capital cut shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, UBS Group decreased their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.50.

ALX Oncology Stock Down 0.7 %

Shares of ALXO opened at $1.33 on Tuesday. ALX Oncology has a 12 month low of $1.30 and a 12 month high of $17.83. The firm’s 50 day moving average is $1.72 and its 200-day moving average is $5.71. The stock has a market capitalization of $70.14 million, a PE ratio of -0.45 and a beta of 1.03. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07.

Institutional Trading of ALX Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of ALXO. Redmile Group LLC lifted its holdings in shares of ALX Oncology by 18.2% during the first quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock worth $48,241,000 after purchasing an additional 667,245 shares during the period. Marshall Wace LLP lifted its holdings in shares of ALX Oncology by 423.0% during the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares during the period. Privium Fund Management B.V. acquired a new position in shares of ALX Oncology during the second quarter worth $2,271,000. Point72 Asset Management L.P. acquired a new position in shares of ALX Oncology during the second quarter worth $1,834,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of ALX Oncology during the third quarter worth $469,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.